A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 28
- Registration Number
- NCT04067518
- Locations
- 🇯🇵
Kobe Children's Hospital Department of Hematology/Oncology, Kobe, Japan
🇯🇵Nagoya Medical Center Department of Pediatrics, Nagoya, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata, Japan
Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Registration Number
- NCT03964025
- Locations
- 🇳🇱
Maastricht Universitair Medisch Centrum, Maastricht, Limburg, Netherlands
🇳🇱Martini Ziekenhuis, Groningen, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
- Conditions
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 856
- Registration Number
- NCT03869892
- Locations
- 🇦🇺
Lake Macquarie Private Hospital, Gateshead, Australia
🇧🇷Hospital de Base Centro Integrado de Pesquisa, São José Do Rio Preto, Brazil
🇮🇪The Adelaide and Meath Hospital, Dublin, Ireland
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 60
- Registration Number
- NCT03755154
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Régionale de Lille Hôpital Huriez, Lille, France
🇫🇷CHU Nantes Hôtel Dieu, Nantes, France
🇫🇷CHU de Nice - Hôpital l'Archet 1 Hématologie clinique, Nice, France
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 211
- Registration Number
- NCT03715153
- Locations
- 🇫🇷
Centre d'Investigation Clinique de Lyon, Bron, Auvergne Rhone Alpes, France
🇵🇱"Niepubliczny Zakład Opieki Zdrowotnej Gdańskie Centrum Zdrowia Sp. z o.o., Gdansk, Poland
🇭🇺Bekes Megyei Kozponti Korhaz Gyermek es ifjusagpszichiatriai osztaly, Gyula, Hungary
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 211
- Registration Number
- NCT03715166
- Locations
- 🇮🇹
Clinica di Neuropsichiatria dell'Infanzia e dell'Adolescenza Ospedale Pediatrico-Microcitemico, Cagliari, Sardegna, Italy
🇮🇹Programma Interdipartimentale "Autismo 0-90" A.O.U. Policlinico "Gaetano Martino", Messina, Sicilia, Italy
🇮🇹U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese, Siena, Toscana, Italy
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 37
- Registration Number
- NCT03672695
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale, New Haven, Connecticut, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, Texas, United States
🇦🇺Peter MacCallum cancer centrer, Melbourne, Australia
Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 49
- Registration Number
- NCT03494712
- Locations
- 🇧🇪
SGS Clinical Pharmacology Unit - Stuivenberg Hospital, Antwerpen, Belgium
Post Marketing Surveillance Study for ONIVYDE® in South Korea
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 94
- Registration Number
- NCT03446872
- Locations
- 🇰🇷
Konyang University Hospital, Daejeon, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷ASAN Medical Center, Seoul, Korea, Republic of
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 123
- Registration Number
- NCT03435250
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States